CKD-508
/ Chong Kun Dang
- LARVOL DELTA
Home
Next
Prev
1 to 5
Of
5
Go to page
1
May 20, 2025
A Drug-drug Interaction Study to Investigate the Pharmacokinetic Interactions Between CKD-508, Midazolam, and Rosuvastatin in Healthy Adult Male Participants
(clinicaltrials.gov)
- P1 | N=24 | Not yet recruiting | Sponsor: Chong Kun Dang Pharmaceutical
New P1 trial
December 10, 2024
A Study to Investigate the Safety, Tolerability, PK, and PD of CKD-508 in Healthy Participants
(clinicaltrials.gov)
- P1 | N=40 | Recruiting | Sponsor: Chong Kun Dang Pharmaceutical
New P1 trial
February 15, 2024
Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=88 | Completed | Sponsor: Chong Kun Dang Pharmaceutical | Recruiting ➔ Completed | Trial completion date: Sep 2022 ➔ Jul 2023 | Trial primary completion date: Sep 2022 ➔ Jul 2023
Trial completion • Trial completion date • Trial primary completion date
February 21, 2022
Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects
(clinicaltrials.gov)
- P1 | N=88 | Recruiting | Sponsor: Chong Kun Dang Pharmaceutical | Trial completion date: May 2021 ➔ Sep 2022 | Trial primary completion date: May 2021 ➔ Sep 2022
Trial completion date • Trial primary completion date
August 07, 2020
Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects
(clinicaltrials.gov)
- P1; N=72; Recruiting; Sponsor: Chong Kun Dang Pharmaceutical
Clinical • New P1 trial
1 to 5
Of
5
Go to page
1